Medicare Price Negotiation Will Disrupt Rebating In Part D; The Question Is How Much

Congressional Budget Office maps out how current rebating practices may change in Medicare Part D under the drug pricing provisions of the Inflation Reduction Act.

Lower Negotiated Prices May Replace Rebates To Part D Plans • Source: Shutterstock

Price discounts conceded to Medicare Part D through negotiation will replace some manufacturer rebates currently provided to plans, leading to a $27bn decline in such rebates in 2031, the Congressional Budget Office projects in a recently-released report.

CBO estimates that net prices for selected drugs will decrease by roughly 50%, on average, as a result of the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet